Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Immuneering (IMRX) Enterprise Value (2021 - 2026)

Immuneering's Enterprise Value history spans 7 years, with the latest figure at -$156.7 million for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 336.89% to -$156.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$156.7 million, a 336.89% decrease, with the full-year FY2025 number at -$172.8 million, down 378.16% from a year prior.
  • Enterprise Value came in at -$156.7 million for Q1 2026, up from -$172.8 million in the prior quarter.
  • The five-year high for Enterprise Value was -$26.4 million in Q2 2025, with the low at -$227.6 million in Q3 2025.
  • Historically, Enterprise Value has averaged -$100.5 million across 5 years, with a median of -$97.2 million in 2023.
  • Biggest five-year swings in Enterprise Value: surged 57.81% in 2024 and later plummeted 378.16% in 2025.
  • Year by year, Enterprise Value stood at -$105.5 million in 2022, then grew by 18.82% to -$85.7 million in 2023, then skyrocketed by 57.81% to -$36.1 million in 2024, then crashed by 378.16% to -$172.8 million in 2025, then rose by 9.34% to -$156.7 million in 2026.
  • Business Quant data shows Enterprise Value for IMRX at -$156.7 million in Q1 2026, -$172.8 million in Q4 2025, and -$227.6 million in Q3 2025.